Safety and Efficacy of the Patent Foramen Ovale Suture System for the Closure of Patent Foramen Ovale

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShenzhen Bihe Medical Co., Ltd

About this trial

A prospective, multicenter, randomized controlled, non-inferiority clinical trial to evaluate the efficacy and safety of the patent foramen ovale suture system in the closure treatment of patent foramen ovale. A parallel controlled comparison will be conducted using the Amplatzer PFO Occluder manufactured by Abbott Medical Devices (Shanghai) co., Ltd. as the control device, to evaluate the safety and efficacy of the Patent Foramen Ovale Suture System in the closure treatment of patent foramen ovale.

Eligibility criteria

Qualifiers

The subject is aged between 18 and 65 years old;

Patent foramen ovale (PFO) confirmed by imaging examination with moderate or greater right-to-left shunt (RLS) (both condition a and b shall be satisfied simultaneously):a) Patent foramen ovale (PFO) confirmed by echocardiography (TTE or TEE);b) Moderate or greater right-to-left shunt confirmed by contrast echocardiography (cTTE, cTEE or cTCD);

Diagnosed as PFO-related stroke/TIA after clinical exclusion of other etiologies;

The subject or legal guardian understands the trial purpose, voluntarily participates in the trial, signs the written informed consent form, and is willing to complete follow-up in accordance with the protocol requirements.

Disqualifiers

Carotid atherosclerotic stenosis (stenosis degree >50% confirmed by ultrasound or CTA);

Large cerebral infarction within 4 weeks (defined by imaging as hypodense area on CT involving more than 1/2 of the MCA perfusion territory, or infarct volume>145 ml on diffusion-weighted imaging (DWI));

Intracardiac thrombus or tumor, intracardiac vegetation;

Acute myocardial infarction or unstable angina within 6 months;

Trial design

Treatments tested in this trial

  • Patent Foramen Ovale Suture System
  • Amplatzer PFO Occluder

Treatment groups

244 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Shenzhen Bihe Medical Co., Ltd

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Collaborator

Fuwai Yunnan Cardiovascular Hospital

Collaborator

The General Hospital of Northern Theater Command

Collaborator

The First Hospital of Hebei Medical University

Collaborator

Qilu Hospital of Shandong University

Collaborator

First Affiliated Hospital, Sun Yat-Sen University

Collaborator

Meizhou People's Hospital

Collaborator

Sichuan Provincial People's Hospital

Collaborator

Lanzhou University Second Hospital

Collaborator

Zibo Central Hospital

Collaborator

Southwest Hospital, China

Collaborator

Second Xiangya Hospital of Central South University

Collaborator